The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.

AUTOR(ES)

Gill, S

RESUMO

Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.

Documentos Relacionados

• HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.
• Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients†
• RNA polymerase II/III transcription specificity determined by TATA box orientation.
• Role of TATA box sequence and orientation in determining RNA polymerase II/III transcription specificity.
• Twice daily versus four times daily treatment with beclomethasone dipropionate in the control of mild childhood asthma.